Preoperative versus postoperative docetaxel-cisplatin- fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial

N. Fazio, R. Biffi, R. Maibach, S. Hayoz, S. Thierstein, P. Brauchli, J. Bernhard, R. Stupp, B. Andreoni, G. Renne, C. Crosta, R. Morant, A. Chiappa, F. Luca, M. G. Zampino, O. Huber, A. Goldhirsch, F. de Braud, A. D. Roth, U. PaceS. Cenciarelli, S. Pozzi, E. Bertani, S. Mura, K. Lorizzo, G. Di Meglio, D. Ravizza, S. Boselli, M. Matter, M. Richter, S. Monfardini, C. Dittrich, M. Häfner, M. Clemens, Susanne Crowe

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)668-673
Number of pages6
JournalAnnals of Oncology
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2016

ASJC Scopus Subject Areas

  • Hematology
  • Oncology

Keywords

  • Chemotherapy
  • Docetaxel
  • Gastric cancer
  • Neoadjuvant
  • Preoperative
  • TCF

Cite this